AEON Biopharma, Inc. (AEON) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 0.48
30Y Low0.5·High0.5
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: N/A
ROE
N/A
—
5yr avg: N/A
Debt/EBITDA
N/A
—
5yr avg: 0.18
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
AEON Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
AEON Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $9M | $11M | $22M | $40.0B | — | — | — | — |
| Enterprise Value | $41M | $44M | $35M | $39.9B | — | — | — | — |
| P/E Ratio → | -0.18 | — | 0.53 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
AEON EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | 0.48 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
AEON Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | 100.0% | 100.0% |
| Operating Margin | — | — | — | — | — | — | -650.8% | -1607.6% |
| Net Profit Margin | — | — | — | — | — | — | -1307.1% | 5151.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — |
| ROA | -901.4% | -901.4% | 841.2% | -4365.1% | -610.6% | -402.4% | -48.6% | 151.2% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | -4971.5% | -28.8% | -55.7% |
AEON Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $33M ($36M total debt minus $3M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | 0.18 | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | 0.18 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -1092.53 | -6.48 |
AEON Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.49x is below 1.0, meaning current liabilities exceed current assets.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.49 | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 | 4.85 | 6.41 |
| Quick Ratio | 0.49 | 0.49 | 0.11 | 0.48 | 0.12 | 0.25 | 4.85 | 6.41 |
| Cash Ratio | 0.44 | 0.44 | 0.00 | 0.40 | 0.12 | 0.25 | 4.81 | 6.39 |
| Asset Turnover | — | — | — | — | — | — | 0.12 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | 29.03 |
AEON Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
AEON Biopharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 187.6% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $10M | $575945 | $77M | $2M | $2M | $91622 | $92301 |
Peer Comparison
Compare AEON with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 AEONYou | $9M | -0.2 | — | — | — | — | — | — | — |
 REVB | $3M | -0.0 | — | — | — | — | -131.4% | — | — |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 ACTU | $48M | -1.9 | — | — | — | — | -553.7% | — | — |
 ABBV | $403B | 96.1 | 16.5 | 22.6 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 ALNY | $38B | 121.4 | 67.0 | 81.1 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 INVA | $2B | 6.9 | 6.8 | 8.6 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 IQV | $31B | 23.1 | 13.1 | 15.0 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -64.4 | 13.0 | 17.4 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 MEDP | $13B | 30.6 | 23.3 | 19.6 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 ICLR | $11B | 50.4 | 10.1 | 13.0 | 26.4% | 12.3% | 2.5% | 6.2% | 2.5 |
| Healthcare Median | — | 22.9 | 14.4 | 18.9 | 63.9% | -4.3% | -32.6% | -11.4% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in AEON 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in AEON be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AEON Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAEON vs REVB — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Revelation Biosciences, Inc..
Compare NowAEON — Frequently Asked Questions
Quick answers to the most common questions about buying AEON stock.
What is AEON Biopharma, Inc.'s P/E ratio?
AEON Biopharma, Inc.'s current P/E ratio is -0.2x. The historical average is 0.5x.
Is AEON stock overvalued?
Based on historical data, AEON Biopharma, Inc. is trading at a P/E of -0.2x. Compare with industry peers and growth rates for a complete picture.